Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: press release

With refreshed brand eXoZymes sharpens pharmaceutical focus to drive platform leverage and long-term value creation
press releaseinvestor
With refreshed brand eXoZymes sharpens pharmaceutical focus to drive platform leverage and long-term value creationFebruary 10, 2026
Pharma-grade NCT ready for partner testing
press releaseinvestornutraceuticalsscience
eXoZymes advancing commercial readiness with profound production metrics on initial NCT pilot runJanuary 29, 2026
100× scale-up of NCT production achieved
press releaseinvestornutraceuticalsmedicine
eXoZymes achieves 100× scale-up of NCT production using exozymes, demonstrating near-perfect feedstock conversionDecember 11, 2025
EXOZ 2025 Q3 Update
press releaseinvestor
eXoZymes provides third quarter 2025 update at 5PM EST todayNovember 13, 2025
CSO Tyler Korman - and Chief of Staff, Amy Lunzer
talentpress releaseinvestor
eXoZymes announces cell-free biomanufacturing pioneer, Tyler Korman, as CSO & Amy Lunzer as Chief of StaffNovember 13, 2025
2025 Q3 Earnings Call
press releaseinvestor
eXoZymes to host third quarter 2025 update on Thursday November 13, 2025, at 5PM ESTNovember 10, 2025
CCO Damien Perriman and co-founder and VP of Development, Dr. Paul Opgenorth.
press releasescience
Driving the cell-free revolution: eXoZymes leaders join BioMADE Leadership & Technical CommitteesSeptember 30, 2025
eXoZymes provides second quarter 2025 update at 5PM EST today
press releaseinvestor
eXoZymes provides second quarter 2025 update at 5PM EST todayAugust 12, 2025
eXoZymes to host second quarter 2025 update on Tuesday August 12, 2025, at 5PM EST
press releaseinvestor
eXoZymes to host second quarter 2025 update on Tuesday August 12, 2025, at 5PM ESTAugust 7, 2025
eXoZymes details biomanufacturing breakthrough: 4 grams of NCT with over 99% purity
press releaseinvestornutraceuticalsvideoscience
eXoZymes details biomanufacturing breakthrough: 4 grams of NCT with over 99% purityJuly 29, 2025
Previous page
Page 1 of 4
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark